Supporting materials
We have compiled helpful resources for funding applications, sample shipping information, and more for the efficient use of Nightingale Health's analysis service.
RemoteOmics
General supporting materials
Information for funding applications
You may find Nightingale Health’s method description and UK Biobank collaboration useful for funding applications, publication writing, or similar purposes. We can also provide you with a Letter of Uniqueness and a Letter of Commitment, if such documents would suit your needs. Please contact us at research(at)nightingalehealth.com for these documents.
Method description
Metabolic biomarkers will be quantified from serum/plasma samples using high-throughput proton NMR metabolomics. The metabolic biomarker assay is unique and innovative by enabling the quantification of 250 metabolites from a small volume of blood. Nightingale’s proprietary metabolic biomarker profiling assay provides an ideal methodology for molecular epidemiology, health tracking, and translation of research findings to clinical use. Nightingale’s blood analysis platform includes both clinically established and emerging biomarkers shown to be medically relevant in large epidemiological studies, and the metabolic profile provides a comprehensive molecular readout of the health state of the subject. More specifically, the analysis provides simultaneous quantification of routine lipids, lipoprotein subclass profiling with lipid concentrations within 14 subclasses, fatty acid composition, inflammation marker GlycA, and various low-molecular metabolites including amino acids, ketone bodies, and glycolysis-related metabolites in absolut concentration units. Over 600 publications to date showcase the stability of the technology and the breadth of scientific applications. Details of the experimentation and applications of the NMR metabolomics platform have been described previously (Soininen et al, Circ Cardiovasc Genet 2015; 8: 192, Würtz et al, Am J Epidemiol 2017;186:1084–1096: Julkunen et al, Nat Commun 2023; 14: 604).
UK Biobank collaboration with Nightingale Health
Nightingale Health’s platform is the first biomarker omics technology to profile the entire UK Biobank collection of 500,000 blood samples. The description of the Nightingale Health data in the UK Biobank resource contains analytical information about the biomarkers, such as measurement repeatability and distributions. The companion document also provides correlations with clinical chemistry and advice on getting started with the epidemiological analysis, applicable also to other cohorts